Neurocrine Biosciences (NASDAQ:NBIX) Shares Break Above 200-Day Moving Average After Insider Selling

Key Points

• Neurocrine shares moved above their 200-day moving average, trading as high as $169.53 and last changing hands at $164.85.
• Third-quarter revenue increased 41% year over year to $1.12 billion, beating estimates; EPS of $3.29 also topped consensus, and the company raised its 2026 INGREZZA sales outlook.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $201.55. A director reported share sales under a pre-arranged Rule 10b5-1 plan.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday after an insider bought additional shares in the company. The stock has a 200-day moving average of $147.60 and traded as high as $169.53. Neurocrine Biosciences shares last traded at $164.85, with a volume of 4,056,875 shares changing hands.

Wall Street Analyst Weigh In

NBIX has been the topic of several recent research reports. Wall Street Zen cut shares of Neurocrine Biosciences from a "buy" rating to a "hold" rating in a research report on Sunday, August 9th. Truist Financial boosted their price objective on Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Piper Sandler increased their price objective on Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Tuesday. Weiss Ratings upgraded Neurocrine Biosciences from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 14th. Finally, TD Cowen lifted their target price on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a "buy" rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $201.55.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Third-quarter revenue rose 41% year over year to $1.12 billion, exceeding estimates, while EPS of $3.29 also topped consensus. Product sales surpassed $1 billion for the first time. Neurocrine raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, citing demand across its portfolio. Third-quarter results
• Positive Sentiment: Several analysts raised price targets after the results: Canaccord to $220, Piper Sandler to $215, RBC to $190, and Morgan Stanley to $185. Ratings ranged from buy/outperform to equal weight, so the target increases were broadly supportive but not uniformly bullish.
• Positive Sentiment: The company said it has begun a Phase 2 Alzheimer’s study and plans to present its neuroscience work and pipeline at the NEI Fall Congress. These updates add to investor focus on longer-term development opportunities, though the supplied reports provide limited study details. Alzheimer’s study and education update
• Negative Sentiment: Director George J. Morrow reported sales totaling 15,000 shares across transactions on November 2–3, in addition to a 300-share sale on October 30. The filings say the transactions were made under a pre-arranged Rule 10b5-1 plan, which may temper concern, and he retained 10,386 shares.

Neurocrine Biosciences Stock Performance

The company has a market capitalization of $16.76 billion, a P/E ratio of 24.46, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. The business has a 50 day moving average of $146.72 and a 200-day moving average of $147.60.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 24.11%. The business had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.04 billion. During the same period in the prior year, the company posted $2.04 EPS. The business's revenue for the quarter was up 41.3% compared to the same quarter last year. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 7.72 EPS for the current fiscal year.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. BlackRock Inc. bought a new position in Neurocrine Biosciences in the second quarter worth about $2,310,886,000. Renaissance Technologies LLC lifted its stake in shares of Neurocrine Biosciences by 8.0% in the 1st quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company's stock valued at $318,665,000 after purchasing an additional 180,100 shares during the period. First Trust Advisors LP boosted its position in shares of Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company's stock valued at $126,367,000 after purchasing an additional 472,408 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Neurocrine Biosciences in the second quarter worth $117,827,000. Finally, Ieq Capital LLC purchased a new stake in Neurocrine Biosciences in the second quarter worth $107,914,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.